Use of inhibition of a gas6 function or of a gas6 receptor for preventing and treating a cardiovascular disease
OwnerPeter Carmeliet, Desire Collen +1inventors
InventorsPeter Carmeliet, Desire Collen, Anne Angelillo-Scherrer
Life of this patent
Estimating the term…
Abstract
An antagonist to the activator of the Rse and Mer receptor protein tyrosine kinases, encoded by growth arrest-specific gene 6 (gas6), is found to be useful in a method of treating an insulin-resistant disorder such as diabetes. More particularly, a method for treating an insulin-resistant disorder is provided which comprises administering to a mammal in need of such treatment an effective amount of a composition comprising a gas6 antagonist. A hypoglycemic agent may be co-administered with the gas6 antagonist.
Claims35
Use of a composition comprising:
- (a) an inhibitor of a Gas6 function or of a Gas6 receptor, or a ribozyme or an antisense RNA directed against Gas 6 or a Gas 6 receptor function, or a protease able to cleave the extracellular domain of the Axl receptor, and
- (b) a thrombolytic agent for the manufacture of a medicine for the prevention or treatment of a thromboembolic disease or a thrombotic pathologic condition in a mammal, in respective proportions such as to provide a synergistic effect in the said prevention or treatment.
A pharmaceutical composition comprising an inhibitor of a Gas6 function or of a Gas6 receptor, or a ribozyme or an antisense RNA directed against Gas 6 or a Gas 6 receptor function, or a protease able to cleave the extracellular domain of the Axl receptor, as an active ingredient in admixture with at least a pharmaceutically acceptable carrier.
Use of inhibition of a Gas6 function or of a Gas6 receptor for the prevention or treatment of a cardiovascular disease other than resulting from an endothelial dysfunction.
Use of an inhibitor of a Gas6 function or of a Gas6 receptor during extracorporeal blood circulation and hemodialysis.
Use of an inhibitor of a Gas6 function or of a Gas6 receptor as a diagnostic agent.
A method of prevention or treatment of a cardiovascular disease resulting from a dysfunction other than an endothelial dysfunction in a mammal, comprising administering to a mammal in need of such prevention or treatment a therapeutically effective amount of an inhibitor of a Gas6 function or of a Gas6 receptor, or a ribozyme or an antisense RNA directed against Gas 6 or a Gas 6 receptor function, or a protease able to cleave the extracellular domain of the Axl receptor.
Dependencies are inferred from the claim text.